The Nomination Committee’s proposal for the annual general meeting in EQL Pharma AB
18 augusti, 11:00
The Nomination Committee’s proposal for the annual general meeting in EQL Pharma AB
Ahead of the annual general meeting on 21 August 2025 in EQL Pharma AB, the Nomination Committee has presented its proposal regarding the election of the board of directors. The Nomination Committee proposes re-election of all board members except Per Ollermark, and the election of Raymond De Vré as a new member of the board.
The Nomination Committee has consisted of Erik Hallengren, representing SEB Fonder, Christer Fåhraeus, representing Fårö Capital AB, and Rajiv I Modi, representing Cadila Pharmaceuticals Limited.
For the annual general meeting, the Nomination Committee proposes:
- that the board shall consist of six ordinary board members,
- that Anders Månsson, Christer Fåhraeus, Linda Neckmar, Per Svangren and Nikunj Shah are re-elected as board members. The current board member Per Ollermark is not available for re-election,
- that Raymond De Vré is elected as new board member, and
- that Christer Fåhraeus is re-elected as chairman of the board.
Information on the person proposed for new election is presented below.
Raymond De Vré (born 1968) has over 25 years of executive-level experience. He lives in Zurich, Switzerland. He currently serves as the Managing Director at RADV Advisory GmbH, an independent strategic and operational advisory company focused on work in the global healthcare, generics and contract development and manufacturing organization (CDMO) space, including for Private Equity owned companies. He is also a non-executive board member at Codexis Inc., a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Prior, he was the CEO of PolyPeptide Group AG, a Swiss-listed API CDMO focused on peptide- and oligonucleotide-based therapies for pharmaceutical and biotech companies globally. While at PolyPeptide, Dr. De Vré was actively involved first in its IPO, then in building up its development and manufacturing infrastructure to sustain the increasing demand for peptides, including GLP1s. Prior to PolyPeptide, Dr. De Vré held multiple senior leadership roles at Dr. Reddy’s Laboratories, including Head of Biologics and member of the Management Committee, during which he led the global expansion of the biosimilar business of Dr Reddy’s. Earlier in his career, he was a Partner at McKinsey & Company, as a member of the pharmaceutical practice, with a special focus on Generics and Global Public Health. Dr. De Vré holds a MSc and PhD in Applied Physics from Stanford University and a master’s degree in engineering from Université Libre de Bruxelles.
Dr. De Vré does not hold any shares in EQL Pharma AB and he is considered independent in relation to the company, its management and major shareholders.
Information on the board members who are proposed for re-election can be found at the company’s website (www.eqlpharma.com/en) and in the annual report.
The Nomination Committee's proposals for the chairman of the meeting as well as election and remuneration of the auditor and remuneration of the board of directors and its committees are presented in the notice convening the annual general meeting.
The annual general meeting will be held on Thursday 21 August 2025 at 16.00 at the company’s premises at Stortorget 1 in Lund.
EQL Pharma AB (publ) in short
EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has 46 niche generics (i.e., generics with limited competition apart from the original drug) launched in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2025 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, mainly in the Nordics and European markets. EQL Pharma AB has its operations in Lund and is listed on Nasdaq Stockholm stock market. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others.
For more information contact:
Axel Schörling,
CEO & President EQL Pharma AB (publ)
Phone: +46 (0) 76 317 90 60
E-mail: axel.schorling@eqlpharma.com
Web: www.eqlpharma.com
Ämnen i artikeln
The Nomination Committee’s proposal for the annual general meeting in EQL Pharma AB
18 augusti, 11:00
The Nomination Committee’s proposal for the annual general meeting in EQL Pharma AB
Ahead of the annual general meeting on 21 August 2025 in EQL Pharma AB, the Nomination Committee has presented its proposal regarding the election of the board of directors. The Nomination Committee proposes re-election of all board members except Per Ollermark, and the election of Raymond De Vré as a new member of the board.
The Nomination Committee has consisted of Erik Hallengren, representing SEB Fonder, Christer Fåhraeus, representing Fårö Capital AB, and Rajiv I Modi, representing Cadila Pharmaceuticals Limited.
For the annual general meeting, the Nomination Committee proposes:
- that the board shall consist of six ordinary board members,
- that Anders Månsson, Christer Fåhraeus, Linda Neckmar, Per Svangren and Nikunj Shah are re-elected as board members. The current board member Per Ollermark is not available for re-election,
- that Raymond De Vré is elected as new board member, and
- that Christer Fåhraeus is re-elected as chairman of the board.
Information on the person proposed for new election is presented below.
Raymond De Vré (born 1968) has over 25 years of executive-level experience. He lives in Zurich, Switzerland. He currently serves as the Managing Director at RADV Advisory GmbH, an independent strategic and operational advisory company focused on work in the global healthcare, generics and contract development and manufacturing organization (CDMO) space, including for Private Equity owned companies. He is also a non-executive board member at Codexis Inc., a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Prior, he was the CEO of PolyPeptide Group AG, a Swiss-listed API CDMO focused on peptide- and oligonucleotide-based therapies for pharmaceutical and biotech companies globally. While at PolyPeptide, Dr. De Vré was actively involved first in its IPO, then in building up its development and manufacturing infrastructure to sustain the increasing demand for peptides, including GLP1s. Prior to PolyPeptide, Dr. De Vré held multiple senior leadership roles at Dr. Reddy’s Laboratories, including Head of Biologics and member of the Management Committee, during which he led the global expansion of the biosimilar business of Dr Reddy’s. Earlier in his career, he was a Partner at McKinsey & Company, as a member of the pharmaceutical practice, with a special focus on Generics and Global Public Health. Dr. De Vré holds a MSc and PhD in Applied Physics from Stanford University and a master’s degree in engineering from Université Libre de Bruxelles.
Dr. De Vré does not hold any shares in EQL Pharma AB and he is considered independent in relation to the company, its management and major shareholders.
Information on the board members who are proposed for re-election can be found at the company’s website (www.eqlpharma.com/en) and in the annual report.
The Nomination Committee's proposals for the chairman of the meeting as well as election and remuneration of the auditor and remuneration of the board of directors and its committees are presented in the notice convening the annual general meeting.
The annual general meeting will be held on Thursday 21 August 2025 at 16.00 at the company’s premises at Stortorget 1 in Lund.
EQL Pharma AB (publ) in short
EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has 46 niche generics (i.e., generics with limited competition apart from the original drug) launched in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2025 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, mainly in the Nordics and European markets. EQL Pharma AB has its operations in Lund and is listed on Nasdaq Stockholm stock market. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others.
For more information contact:
Axel Schörling,
CEO & President EQL Pharma AB (publ)
Phone: +46 (0) 76 317 90 60
E-mail: axel.schorling@eqlpharma.com
Web: www.eqlpharma.com
Ämnen i artikeln
Aktier
Aktierekommendationer
Bostadsmarknaden
Selins sorti
Aktier
Mest läst
Aktierekommendationer
Bostadsmarknaden
Selins sorti
Senaste nytt
Marknadsöversikt
OMX Stockholm 30
1 DAG %
−0,17%
Senast
2 655,24
1 mån
Loading market data...
